ACACADIA Pharmaceuticals ACAD · NASDAQ
$20.31 +0.59% (+$0.12)
- Market cap
- $3.41B
- Enterprise value
- $3.10B
- P/E
- 9.0x
- Forward P/E
- 32.9x
- PEG
- 0.1x
- P/S
- 3.0x
- P/FCF
- 19.6x
- EV/EBITDA
- 26.7x
- ROIC
- 19.4%
- Gross margin
- 91.1%
- Net margin
- 33.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -2.7x
- Beta
- 0.89
- Free float
- 98.7%
About the company
ACADIA Pharmaceuticals Inc. (ACAD) is an American biopharmaceutical company focusing on the development of innovative drugs for the treatment of central nervous system disorders. Their main product, pimavanserin, is an approved medication for the treatment of hallucinations and delusions associated with Parkinson's disease. ACADIA Pharmaceuticals actively engages in clinical trials and research to discover new therapeutic options for patients suffering from neurological disorders. ACADIA Pharmaceuticals Inc. (ACAD) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on innovative treatment approaches for neurological conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
Catherine E. Owen Adams
Employees
797
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number